デフォルト表紙
市場調査レポート
商品コード
1319107

ペプチド抗生物質市場:タイプ別、疾患別、投与経路別、流通チャネル別-2023~2030年の世界予測

Peptide Antibiotics Market by Type, Disease, Route of Administration, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 184 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
ペプチド抗生物質市場:タイプ別、疾患別、投与経路別、流通チャネル別-2023~2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ペプチド抗生物質の世界市場は大きく成長し、2023年にはCAGR 9.67%で51億1,109万米ドルが予測され、2030年には驚異的な98億39万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のペプチド抗生物質市場を評価するために不可欠です。事業戦略や製品満足度などの主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展:有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化:新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向:COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報:主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション:将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします:

1.ペプチド抗生物質の世界市場規模および予測は?

2.予測期間中、世界のペプチド抗生物質市場を形成するCOVID-19の阻害要因と影響は?

3.ペプチド抗生物質の世界市場において予測期間中に投資すべき製品/セグメント/用途/分野は?

4.ペプチド抗生物質の世界市場における競争戦略は?

5.ペプチド抗生物質の世界市場における技術動向と規制の枠組みは?

6.ペプチド抗生物質の世界市場における主要ベンダーの市場シェアは?

7.ペプチド抗生物質の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 細菌性皮膚、血流、病院感染などの病気の有病率の増加
      • 病院やクリニックでのペプチド抗生物質のニーズの高まり
      • 医療インフラ施設の改善
    • 抑制要因
      • 厳格な返金政策
    • 機会
      • 製品承認、製品発売、研究開発の取り組みの増加
      • 皮膚/骨の再生、インプラント関連感染症の予防、がん治療、遺伝子送達における新たな用途
    • 課題
      • ペプチド抗生物質の不安定性と毒性に関する懸念
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 ペプチド抗生物質市場:タイプ別

  • イントロダクション
  • 非リボソーム合成
  • リボソーム合成

第7章 ペプチド抗生物質市場:疾患別

  • イントロダクション
  • 血流感染症
  • HABP/VABP
  • 皮膚感染症

第8章 ペプチド抗生物質市場:投与経路別

  • イントロダクション
  • 注射
  • 経口
  • 局所

第9章 ペプチド抗生物質市場:流通チャネル別

  • イントロダクション
  • 病院薬局
  • オンライン薬局
  • 小売薬局

第10章 南北アメリカのペプチド抗生物質市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域のペプチド抗生物質市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカのペプチド抗生物質市場

  • イントロダクション
  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ分析:主要企業別

第14章 掲載企業一覧

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. PEPTIDE ANTIBIOTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PEPTIDE ANTIBIOTICS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. PEPTIDE ANTIBIOTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
  • FIGURE 5. PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2022 VS 2030 (%)
  • FIGURE 6. PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
  • FIGURE 7. PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 8. PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 9. PEPTIDE ANTIBIOTICS MARKET DYNAMICS
  • FIGURE 10. PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. PEPTIDE ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 19. PEPTIDE ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. PEPTIDE ANTIBIOTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. PEPTIDE ANTIBIOTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. PEPTIDE ANTIBIOTICS MARKET SIZE, BY NON-RIBOSOMAL SYNTHESIZED PEPTIDE ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. PEPTIDE ANTIBIOTICS MARKET SIZE, BY RIBOSOMAL SYNTHESIZED PEPTIDE ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 8. PEPTIDE ANTIBIOTICS MARKET SIZE, BY BLOOD STREAM INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. PEPTIDE ANTIBIOTICS MARKET SIZE, BY HABP/VABP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. PEPTIDE ANTIBIOTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. PEPTIDE ANTIBIOTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. PEPTIDE ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. PEPTIDE ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. PEPTIDE ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 188. PEPTIDE ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 189. PEPTIDE ANTIBIOTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-205091A88A2E

The Global Peptide Antibiotics Market is forecasted to grow significantly, with a projected USD 5,111.09 million in 2023 at a CAGR of 9.67% and expected to reach a staggering USD 9,800.39 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Peptide Antibiotics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Peptide Antibiotics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Non-Ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics. The Ribosomal Synthesized Peptide Antibiotics is projected to witness significant market share during forecast period.

Based on Disease, market is studied across Blood Stream Infections, HABP/VABP, and Skin Infections. The Skin Infections is projected to witness significant market share during forecast period.

Based on Route of Administration, market is studied across Injectable, Oral, and Topical. The Oral is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Hospital Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Peptide Antibiotics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Peptide Antibiotics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Peptide Antibiotics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Peptide Antibiotics Market?

4. What is the competitive strategic window for opportunities in the Global Peptide Antibiotics Market?

5. What are the technology trends and regulatory frameworks in the Global Peptide Antibiotics Market?

6. What is the market share of the leading vendors in the Global Peptide Antibiotics Market?

7. What modes and strategic moves are considered suitable for entering the Global Peptide Antibiotics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Peptide Antibiotics Market, by Type, 2022 vs 2030
  • 4.3. Peptide Antibiotics Market, by Disease, 2022 vs 2030
  • 4.4. Peptide Antibiotics Market, by Route of Administration, 2022 vs 2030
  • 4.5. Peptide Antibiotics Market, by Distribution Channel, 2022 vs 2030
  • 4.6. Peptide Antibiotics Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diseases such as bacterial skin, blood stream, and hospital acquired infections
      • 5.1.1.2. Rising need for peptide antibiotics in hospitals and clinics
      • 5.1.1.3. Improvement in healthcare infrastructure facility
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent reimbursement policy
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising product approvals and product launches and R&D initiatives
      • 5.1.3.2. Emerging use in regeneration of skin/bone, prevention of implant-associated infections, cancer therapy and gene delivery
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns related to instability and toxicity of peptide antibiotics
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Peptide Antibiotics Market, by Type

  • 6.1. Introduction
  • 6.2. Non-Ribosomal Synthesized Peptide Antibiotics
  • 6.3. Ribosomal Synthesized Peptide Antibiotics

7. Peptide Antibiotics Market, by Disease

  • 7.1. Introduction
  • 7.2. Blood Stream Infections
  • 7.3. HABP/VABP
  • 7.4. Skin Infections

8. Peptide Antibiotics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral
  • 8.4. Topical

9. Peptide Antibiotics Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Peptide Antibiotics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Peptide Antibiotics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Peptide Antibiotics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing